Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Apr 15, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The DIPLOMA-3 trial is a research study comparing two types of surgery for patients needing a left-sided pancreatectomy, which is the removal of part of the pancreas. This surgery is being studied for patients with non-cancerous or potentially cancerous conditions affecting the body or tail of the pancreas. The two methods being compared are laparoscopic surgery, which uses small incisions and special instruments, and robot-assisted surgery, which uses robotic technology to assist the surgeon. The goal is to see which method is safer and more effective for patients.
To be eligible for this trial, participants must be at least 18 years old and have a specific need for this type of surgery, as determined by their doctors. They should also be healthy enough to undergo the procedure, and both surgical options should be suitable for their situation. Patients will be randomly assigned to one of the two surgical methods, but they won’t know which one they are receiving to ensure a fair comparison. The trial is not yet recruiting participants, so those interested will need to wait for it to begin.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age at least 18 years;
- • Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease);
- • Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team;
- • Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist;
- • Written informed consent
- Exclusion Criteria:
- • Suspected pancreatic ductal adenocarcinoma;
- • Tumor or cyst larger than 8 cm;
- • Required resection or ablation of organs other than pancreas and spleen;
- • Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava);
- • Pregnancy;
- • Body mass index \>40 kg/m2;
- • Participation in another study with interference of study outcomes
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Prof. Mohammad Abu Hilal, MD PhD
Principal Investigator
University of Jordan
Prof. Marc Besselink, MD, PhD
Principal Investigator
Amsterdam UMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported